Previous Play Slide ShowStop Slide Show Next
PreSep 中心静脉氧饱和度导管 (ScvO2)
用 PreSep 血氧监测导管进行连续 ScvO2监测可以揭示传统生命体征难以察觉的隐蔽组织缺氧。 ScvO29 的预后值已经在以下几方面显示出来:术后高风险手术、1创伤、2 败血症、4,5 在 CHF 时的心脏衰竭3,5、心跳骤停复苏6,7

有助于指导治疗并开始早期介入治疗
  • 连续 ScvO2 与间歇取样和单独的传统生命体征相比,是一个更敏感的组织灌注指标8-10, 3
  • 连续 ScvO2 监测揭示了组织氧合的真正充分度,可及时发现并评价对介入的临床反应8,9
方便、精确且易于使用
  • 首个经证实的配有连续 ScvO2 监测的三腔导管
  • 设计与 Edwards 血氧监护仪 (如 Vigileo) 和光缆配合使用
连续 ScvO2 监测也可配用置入式 Oligon 抗菌††材料,这种材料从置入式聚合物上释放银离子(Ag+),并不会像抗菌涂层一样被洗掉。
  • 可防止感染革兰氏阴性菌、革兰氏阳性菌以及真菌和耐药微生物菌株
  • 在一项于十所院校进行的前瞻性随机试验中,导管的微生物定植率同标准导管相比显著降低 11
  • 在另一项使用其它抗菌导管的研究中,将导管相关的感染降低达 48%12


参考文献:
1. Pearse, R, et al. Changes in central venous saturation after major surgery, and association with outcome. Crit Care 2005;9(6):R694-91. Reinhart, K, et al. Continuous central venous and pulmonary artery oxygen saturation monitoring in the critically ill. Intensive Care Med 2004;30(8):1572-8.
2. Scalea, TM, et al. Central venous oxygen saturation: a useful clinical tool in trauma patients. J Trauma 1990;30(12):1539-43.
3. Ander, DS, et al. Undetected cardiogenic shock in patients with congestive heart failure presenting to the emergency department. Am J Cardiol 1998;82(7):888-91.
4. Rivers, EP, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345(19):1368-77.
5. Rady, MY, et al. Resuscitation of the critically ill in the ED: responses of blood pressure, heart rate, shock index, central venous oxygen saturation, and lactate. Am J Emerg Med 1996;14(2):218-25.
6. Nakazawa, K, et al. Usefulness of central venous oxygen saturation monitoring during cardiopulmonary resuscitation. A comparative case study with end-tidal carbon dioxide monitoring. Intensive Care Med 1994;20(6):450-1.
7. Rivers, EP, et al. The clinical implications of continuous central venous oxygen saturation during human CPR. Ann Emerg Med 1992;21(9):1094-101.
8. Reinhart, K, et al. Continuous central venous and pulmonary artery oxygen saturation monitoring in the critically ill. Intensive Care Med 2004;30(8):1572-8.
9. Rivers, EP, et al. Central venous oxygen saturation monitoring in the critically ill patient. Curr Opin Crit Care 2001;7(3):204-11.
10. Ingelmo, P, et al. Importance of monitoring in high risk surgical patients. Minerva Anestesiol 2002;68(4):226-30.
11. Ranucci M, et al. Impact of oligon central venous catheters on catheter colonization and catheter-related bloodstream infection. Crit Care Med 2003;31(1):52-9.
12. Garcia, R, et al. Three years experience in implementing HICPAC recommendations for the reduction of central venous catheter-related bloodstream infections. Poster presentation at National APIC meeting, June 2003.

††††抗菌剂活性位于导管表层且不适用于系统性感染处理。体外试验表明,Oligon 材料对以下试验菌具有广谱效果(≥3 log,在 48 小时内从初浓度开始下降): 金色葡萄球菌、葡萄球菌、肺炎克雷伯菌、粪肠球菌、白色念珠菌、大肠杆菌、粘质沙雷氏菌、醋酸钙不动杆菌、白喉杆菌、产气肠杆菌、GMRSa、绿脓杆菌、光滑假丝酵母菌和 VRE(屎肠球菌)。

Early Goal-Directed Therapy and EGDT are trademarks of Dr. Emanuel Rivers.
Oligon is a trademark of Implemed, Inc.

供专业人士使用。 请查阅使用说明以了解完整的处方信息,包括: 适应症、禁忌、警告、预防措施和副作用。